Newsroom
Top Results
Sight Sciences Announces Publication of Favorable Two-Year Outcomes of Standalone Use of the OMNI® Surgical System in Mild to Moderate Open-Angle Glaucoma
Pioneering the Development of the Standalone MIGS Market, this Real-world data published in Clinical Ophthalmology show the safety, efficacy, and durability of effect of OMNI for use in a standalone procedure to reduce intraocular pressure and medication burden
Sight Sciences Reports Second Quarter 2021 Financial Results
MENLO PARK, Calif., August 12, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today reported financial results for the quarter ended June 30, 2021. Recent Business Highlights • Generated second quarter 2021 total revenue of […]
Sight Sciences to Report Second Quarter 2021 Financial Results on August 12, 2021
MENLO PARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) today announced it will report financial results for the second quarter 2021 after the market close on Thursday, August 12, 2021. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. […]
Sight Sciences Announces Multiple Presentations at the 2021 American Society of Cataract and Refractive Surgery Annual Meeting
New safety and efficacy data from both retrospective and prospective studies of the OMNI Surgical System and a prospective study of the TearCare System to be presented
Sight Sciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Sight Sciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Sight Sciences Announces Pricing of Initial Public Offering
Sight Sciences Announces Pricing of Initial Public Offering
Sight Sciences Announces Substantial Crossover Raise
Funds will be used to continue clinical and commercial acceleration
Sight Sciences Appoints Donald J. Zurbay to Company’s Board of Directors
Highly accomplished industry executive brings financial and operational expertise to innovative eye care company